What is HC Wainwright’s Estimate for HRMY FY2026 Earnings?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Harmony Biosciences in a research note issued on Thursday, November 12th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $3.37 for the year, down from their prior forecast of $3.52. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.65 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.73 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $4.50 EPS, FY2028 earnings at $6.06 EPS, FY2029 earnings at $5.90 EPS and FY2030 earnings at $7.30 EPS.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. The company had revenue of $268.92 million for the quarter, compared to analysts’ expectations of $272.05 million. During the same period in the prior year, the firm posted $1.08 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis.

Other equities research analysts have also issued research reports about the company. Truist Financial boosted their price target on Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. WBB Securities raised Harmony Biosciences to a “hold” rating in a research note on Friday, October 23rd. Mizuho set a $49.00 price objective on Harmony Biosciences in a report on Thursday, October 29th. Weiss Ratings cut Harmony Biosciences from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, Oppenheimer reiterated an “outperform” rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.00.

Harmony Biosciences Trading Down 1.2%

Shares of Harmony Biosciences stock opened at $33.80 on Friday. The company has a 50-day moving average of $38.81 and a two-hundred day moving average of $34.64. Harmony Biosciences has a 12-month low of $25.90 and a 12-month high of $43.49. The company has a current ratio of 3.44, a quick ratio of 3.42 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.98 billion, a PE ratio of 11.33, a price-to-earnings-growth ratio of 0.35 and a beta of 1.00.

Institutional Trading of Harmony Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Harmony Biosciences during the 2nd quarter worth approximately $258,583,000. Allspring Global Investments Holdings LLC increased its position in Harmony Biosciences by 548.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,124,717 shares of the company’s stock worth $44,505,000 after buying an additional 951,273 shares in the last quarter. venBio Partners LLC purchased a new position in Harmony Biosciences during the second quarter worth $17,192,584. Boston Partners increased its position in Harmony Biosciences by 1,289.9% during the third quarter. Boston Partners now owns 423,647 shares of the company’s stock worth $16,638,000 after buying an additional 393,166 shares in the last quarter. Finally, Tieton Capital Management LLC acquired a new position in shares of Harmony Biosciences in the second quarter worth $11,170,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Insiders Place Their Bets

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the completion of the transaction, the insider directly owned 13,115 shares in the company, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 72,406 shares of company stock worth $3,108,520. Company insiders own 11.00% of the company’s stock.

Key Harmony Biosciences News

Here’s some of the latest news about HRMY:

• Positive Sentiment: HC Wainwright raised its EPS estimates for 2028, 2029 and 2030 to $6.06, $5.90 and $7.30, respectively, and maintained a $55 price target—suggesting stronger projected earnings further out. HC Wainwright Buy rating article
• Negative Sentiment: The analyst cut EPS estimates for FY2026 to $3.37 from $3.52 and FY2027 to $4.50 from $4.69, alongside reductions to its Q4 2026 and Q2–Q4 2027 forecasts. These downward revisions point to softer expected near-term earnings.
• Negative Sentiment: Recent results also showed earnings pressure despite 12.3% year-over-year revenue growth: quarterly EPS of $0.81 fell short of the $1.09 consensus, and revenue was slightly below expectations. Harmony Biosciences profit and sales article

Harmony Biosciences Company Profile

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.